SynthesisLiver international : official journal of the International Association for the Study of the Liver2026
Network Meta-Analysis: Treatments for Acute Alcohol-Associated Hepatitis.
Synthesis in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Network Meta-Analysis: Treatments for Acute Alcohol-Associated Hepatitis.Liver international : official journal of the International Association for the Study of the Liver · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlcohol-related hepatitis (AH) is an acute form of liver disease with a high short-term mortality. A variety of treatments have been explored in randomised studies. Recent consensus on study outcomes has identified 90-day survival as the primary outcome metric.
aimsThis systematic review and network meta-analysis is to update understanding of the comparative efficacy of treatments for AH, based on 90-day survival, to inform future Phase III studies.
methodsPubMed, Ovid-Medline and Embase were searched for randomised studies of treatments of AH. The risk of bias in included papers was measured using the Cochrane risk of bias 2 tool. Data were synthesised with network meta-analysis to estimate risk ratio (RR) of survival at 90 days after randomisation. Heterogeneity was assessed with the magnitude of the between-study variance (tau
resultsThirty five studies including 5045 participants were identified that examined 24 treatments for AH. Twenty-three studies were considered to be at low risk of bias. In network meta-analysis considering placebo as the reference treatment, only granulocyte colony stimulating factor (GCSF) showed a statistically significant benefit on 90-day mortality (RR 0.49, 95% CI 0.28-0.84; p = 0.009). In subgroup analysis of studies at low risk of bias, no treatments showed a significant effect on mortality at 90 days.
conclusionsIndividual studies are small and heterogeneity is marked; however, some agents show promise to improve survival at 90 days in people with AH. This information should inform adequately powered studies to explore potential treatments for AH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.